These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3768021

  • 1. The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat.
    Thijssen HH, Janssen CA, Drittij-Reijnders MJ.
    Biochem Pharmacol; 1986 Oct 01; 35(19):3277-82. PubMed ID: 3768021
    [Abstract] [Full Text] [Related]

  • 2. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat.
    de Boer-van den Berg MA, Thijssen HH, Vermeer C.
    Biochim Biophys Acta; 1986 Oct 29; 884(1):150-7. PubMed ID: 3490277
    [Abstract] [Full Text] [Related]

  • 3. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes.
    Fasco MJ, Principe LM, Walsh WA, Friedman PA.
    Biochemistry; 1983 Nov 22; 22(24):5655-60. PubMed ID: 6652076
    [Abstract] [Full Text] [Related]

  • 4. Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin.
    Thijssen HH.
    Biochem Pharmacol; 1987 Sep 01; 36(17):2753-7. PubMed ID: 3632704
    [Abstract] [Full Text] [Related]

  • 5. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.
    Thijssen HH, Baars LG, Vervoort-Peters HT.
    Br J Pharmacol; 1988 Nov 01; 95(3):675-82. PubMed ID: 3207986
    [Abstract] [Full Text] [Related]

  • 6. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase.
    Thijssen HH, Baars LG.
    Biochem Pharmacol; 1989 Apr 01; 38(7):1115-20. PubMed ID: 2706010
    [Abstract] [Full Text] [Related]

  • 7. Tissue distribution and warfarin sensitivity of vitamin K epoxide reductase.
    Hazelett SE, Preusch PC.
    Biochem Pharmacol; 1988 Mar 01; 37(5):929-34. PubMed ID: 3345202
    [Abstract] [Full Text] [Related]

  • 8. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat.
    Mosterd JJ, Thijssen HH.
    J Pharmacol Exp Ther; 1992 Mar 01; 260(3):1081-5. PubMed ID: 1545379
    [Abstract] [Full Text] [Related]

  • 9. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats.
    MacNicoll AD.
    Biochim Biophys Acta; 1985 May 29; 840(1):13-20. PubMed ID: 3995080
    [Abstract] [Full Text] [Related]

  • 10. Tissue distribution of selective warfarin binding sites in the rat.
    Thijssen HH, Baars LG.
    Biochem Pharmacol; 1991 Nov 06; 42(11):2181-6. PubMed ID: 1958236
    [Abstract] [Full Text] [Related]

  • 11. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes.
    Hildebrandt EF, Preusch PC, Patterson JL, Suttie JW.
    Arch Biochem Biophys; 1984 Feb 01; 228(2):480-92. PubMed ID: 6696443
    [Abstract] [Full Text] [Related]

  • 12. Evidence that warfarin anticoagulant action involves two distinct reductase activities.
    Fasco MJ, Hildebrandt EF, Suttie JW.
    J Biol Chem; 1982 Oct 10; 257(19):11210-2. PubMed ID: 6811577
    [Abstract] [Full Text] [Related]

  • 13. R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat.
    Fasco MJ, Principe LM.
    J Biol Chem; 1982 May 10; 257(9):4894-901. PubMed ID: 7068669
    [Abstract] [Full Text] [Related]

  • 14. Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase.
    Thijssen HH, Baars LG.
    J Pharmacol Exp Ther; 1987 Dec 10; 243(3):1082-8. PubMed ID: 3694526
    [Abstract] [Full Text] [Related]

  • 15. Vitamin-K-dependent proteins in microsomes of primary Lewis lung tumors.
    Wilson AC, Fasco MJ.
    Int J Cancer; 1986 Dec 15; 38(6):877-82. PubMed ID: 3793264
    [Abstract] [Full Text] [Related]

  • 16. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.
    Yamanaka Y, Yamano M, Yasunaga K, Shike T, Uchida K.
    Thromb Res; 1990 Jan 15; 57(2):205-14. PubMed ID: 2315885
    [Abstract] [Full Text] [Related]

  • 17. Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase.
    Preusch PC, Suttie JW.
    Arch Biochem Biophys; 1984 Nov 01; 234(2):405-12. PubMed ID: 6497379
    [Abstract] [Full Text] [Related]

  • 18. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.
    Guenthner TM, Cai D, Wallin R.
    Biochem Pharmacol; 1998 Jan 15; 55(2):169-75. PubMed ID: 9448739
    [Abstract] [Full Text] [Related]

  • 19. Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents.
    Thijssen HH, Janssen YP, Vervoort LT.
    Biochem J; 1994 Jan 15; 297 ( Pt 2)(Pt 2):277-80. PubMed ID: 8297331
    [Abstract] [Full Text] [Related]

  • 20. Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase.
    Creedon KA, Suttie JW.
    Thromb Res; 1986 Oct 15; 44(2):147-53. PubMed ID: 3787564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.